What medicine is Asiminib and price details

Asciminib, English nameAsciminib, is a new drug developed by Novartis, mainly used to treat chronic myelogenous leukemia (CML). Aceminib is a rare cancer caused by chromosomal abnormalities. Acemini was approved by the US FDA on October 29, 2021 (Scemblix, Novartis AG).

Aximinib is a tyrosine kinase inhibitor, specifically targeted at Philadelphia chromosome-positive (Ph+) CML patients. It works by inhibiting the activity of the abnormal protein Bcr-Abl in leukemia cells. This abnormal protein plays a key role in chronic myelogenous leukemia and is responsible for the abnormal proliferation of leukemia cells. Acemini targets this abnormal protein and inhibits its activity, thereby reducing the proliferation and spread of leukemia cells.

In clinical trials, aceminib showed remarkable efficacy. Especially when treating patients who are ineffective or poorly tolerated by other drug treatments, aceminib has shown its unique advantages. It can inhibit the growth of leukemia cells to a certain extent and reduce the damage of leukemia cells to normal cells, thereby improving the patient's quality of life.

In addition, the mechanism of action of Aceminib is more precise than traditional treatment methods. It works by targeting a specific region of the BCR-ABL fusion gene, blocking the growth and spread of leukemia cells. This new type of drug binds to abnormal proteins and prevents them from working, thereby reducing the number of leukemia cells and helping patients control the disease.

However, like other drugs, Aceminid may cause side effects such as nausea, vomiting, diarrhea, fatigue, etc. Therefore, it is necessary to closely monitor the patient's body response during use and make adjustments under the guidance of a doctor.

Aximini is not currently on the market in China, and domestic patients have no way to directly purchase it. It is understood that the original research version of Acemini is relatively expensive. The price of 40mg*60 tablets is around 150,000 yuan, which is quite expensive. In addition, there are imitation versions of Asimini available overseas. The imitation version of Asimini available overseas was launched by Lucius in Laos, and its specifications are40mg*60 tablets, the price is about 4,500 yuan.

In general, as a new type of leukemia treatment drug, aceminib brings new treatment options to patients with chronic myelogenous leukemia with its unique mechanism of action and significant clinical effects. If you have more questions about Acemini, you can consult a regular overseas medical consulting company for more information.